Calls
1
Will Lewis
CEO, Insmed
Win Rate
0.0%
return
-29.9%
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Jan 12
$176.90
-29.9%
Insmed has two marketed rare-disease drugs, ARIKAYCE and its bronchiectasis drug, with strong commercial performance: Q4 preliminary data showed more than 9,000 bronchiectasis patients and $144.6M revenue, while ARIKAYCE exceeded raised guidance. The company also has near-term pipeline catalysts, a balance sheet that can fund commercialization, and business-development optionality, supporting further growth.
Pharma & Biotech
Showing 1 of 1 calls · sorted by mentions
Choose a mentions count to open ticker posts.
Will Lewis has 1 trade ideas tracked on Buzzberg across 1 tickers since January 2026. Most covered: INSM.
Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology
